Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Neoplasms 2Breast Neoplasms 2Urogenital Neoplasms 1Stage II Prostate Adenocarcinoma 1Prostate Adenocarcinoma 1Neoplasms by Site 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

padeliporfin 5Abiraterone Acetate 3Pluvicto 2Paclitaxel 2sipuleucel-T 1rucaparib 1pembrolizumab 1palladium-bacteriopheophorbide 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1ixabepilone 1gallium 68 PSMA-11 1apalutamide 1abiraterone 1Therapeutics 1Suspensions 1Radiotherapy 1Radiation Dose Hypofractionation 1Powders 1Nivolumab 1Leuprolide 1Ipilimumab 1Imatinib Mesylate 1Gemcitabine 1EPI-506 1Cisplatin 1Chemical Fractionation 1Biopsy, Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Male × BAY 86-7548 × Clear all
NCT02483884 2017-03-22

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Lantheus Biosciences Ltd.

Phase 1/2 Terminated
30 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡